| アブストラクト | INTRODUCTION: Sotorasib and adagrasib have been widely used for the non-small cell lung cancer (NSCLC) patients harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutation. It's necessary to assess their safety profiles in the real-world population. METHODS: A retrospective pharmacovigilance was conducted to examine adverse events (AEs) associated with sotorasib and adagrasib therapies using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Disproportionality analysis was performed employing Venn analysis and four data-mining algorithms, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS). RESULTS: The most commonly reported system organ classes (SOCs) for both adagrasib and sororasib were general, gastrointestinal, and investigations disorders. Notably, sotorasib exhibited significant signals for neoplasms and hepatobiliary disorders in four algorithms. Specifically, AEs related to neoplasms were predominantly associated with lung malignancies, all of which were consistent with the therapeutic indications of KRAS G12C mutation inhibitor. A total of 19 common AEs were identified in sotorasib and adagrasib, spanning gastrointestinal, general, hepatobiliary, investigations, metabolism, musculoskeletal, neoplasms, and respiratory disorders. 4 severe AEs (SAEs) were identified in sotorasib, with 3 SAEs displaying significant signals in four algorithms, including drug-induced liver injury, pancreatitis, and hepatic failure. In adagrasib, only 2 SAEs were detected, with renal failure showing significant signals in four algorithms. CONCLUSION: This study offers a comprehensive evaluation of the major safety signals associated with sotorasib and adagrasib, providing valuable information for clinicians regarding drug selection and safety considerations, thereby facilitating the design of future prospective safety studies. |
|---|
| ジャーナル名 | Frontiers in pharmacology |
|---|
| Pubmed追加日 | 2024/9/12 |
|---|
| 投稿者 | Wu, Lisha; Xu, Maosheng; Li, Xueqin; Aierken, Dilinuer; Yu, Jinxiu; Qin, Tao |
|---|
| 組織名 | Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University,;Guangzhou, Guangdong, China.;Department of Oncology, Shenshan Medical Center, Sun Yat-sen Memorial Hospital,;Sun Yat-sen University, Shanwei, Guangdong, China.;Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39263575/ |
|---|
